Latest Pasteur Institute Stories
PARIS, December 18, 2014 /PRNewswire/ -- ABIVAX, a leading clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, is pleased
PARIS, December 1, 2014 /PRNewswire/ -- Institut Pasteur, research institute of excellence in science, medicine and public health since 1887, and a network of 32 Institut
PARIS, November 12, 2014 /PRNewswire/ -- ABIVAX, a leading European, clinical stage biopharmaceutical company developing and commercializing anti-viral compounds and human
Spreading the word about rabies vaccination through GARC's "Me and My Dog - Together Against Rabies" campaign LYON, France, Sept.
VIENNA, June 12, 2014 /PRNewswire/ -- A prophylactic vaccine candidate against Chikungunya fever, developed by the Austrian biotech company Themis Bioscience GmbH induces
When most people hear of the bubonic plague they tend to think of the Black Death pandemic that swept through the western world in the Middle Ages, wiping out nearly a quarter of the world’s population.
Today, at a scientific meeting at Institut Pasteur, France, entitled ‘Best Science for the Most Neglected: Where Do We Stand Ten Years On?’, co-organized with Institut Pasteur and MSF and in collaboration with PLOS, the Drugs for Neglected Diseases initiative (DNDi) marks its 10-year anniversary by issuing a report that explores the lessons learned from a decade of research and development (R&D) of new treatments for neglected diseases via a cost-effective, innovative, not-for-profit drug...
It is rare that an unpublished piece of research or theory remains significant after half a century.
An international collaboration of researchers from the U.S. Army Medical Research and Materiel Command (USAMRMC), Tunisia and France has demonstrated a high cure rate and remarkably few side effects in treating patients with cutaneous leishmaniasis (CL) with an investigational antibiotic cream.
- totally perplexed and mixed up.